Tomoko Maeda‐Chubachi

Author

Also Known As

Astrid H. Lossius, Green, Lawrence J., T Maeda-Chubachi, T. Maeda-Chubachi, T. Maeda‐Chubachi, Tomoko Maeda-Chubachi, Tomoko Maeda‐Chubachi

Publications

910

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Jupiter Medical Center Pfizer (United States)Northwestern University University of Utah

About

Tomoko Maeda‐Chubachi is an author at Eli Lilly (United States) specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	439
2	Immunology	2	2	92
3	Pharmacology	2	2	247
4	Public Health	1	1	32
5	Microbiology	1	1	10

Tomoko Maeda‐Chubachi

Publications

814

Citations

H-Index

Page 1

	Year	Citations
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis Johnny Peppers, Amy S. Paller, Tomoko Maeda‐Chubachi, Journal of the American Academy of Dermatology Dose-finding StudyRheumatologyAtopic DermatitisMedicineClinical Dermatology	2018	157
Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink Emily Edson‐Heredia, Baojin Zhu, C. Lefèvre, Journal of the European Academy of Dermatology and Venereology	2014	94
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis K. Thomas Robbins, Robert Bissonnette, Tomoko Maeda‐Chubachi, Journal of the American Academy of Dermatology Dose-finding StudyPharmacologyPsoriatic ArthritisPlaque PsoriasisClinical Dermatology	2018	90
Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis Emily Edson‐Heredia, K.L. Sterling, Carlos Alatorre, Journal of Investigative Dermatology Biologic TreatmentMedicineImmunologyClinical DermatologyDermatology	2013	82
Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial Baojin Zhu, Emily Edson‐Heredia, Jiaying Guo, British Journal of Dermatology	2014	62
Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study Tomoko Maeda‐Chubachi, Katherine Chi-Burris, Brad D. Simons, Ophthalmology OphthalmologyDouble-masked Multicenter StudyEye HealthPediatric OphthalmologyGlaucoma	2011	41
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study Robert Bissonnette, Lakshmi Vasist, Jonathan Bullman, Clinical Pharmacology in Drug Development	2018	39
Efficacy and tolerability of an investigational nitric oxide–releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial Adelaide A. Hebert, Elaine C. Siegfried, Todd A. Durham, Journal of the American Academy of Dermatology	2019	37
Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. Emily Edson‐Heredia, Baojin Zhu, Jiaying Guo, PubMed Quality Of LifeLife AssessmentComorbid Psoriatic ArthritisDisease BurdenDermatology	2015	32
Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum John Browning, Carolyn Enloe, Martina Cartwright, JAMA Dermatology	2022	29

Page 1